PhRMA testifies to Congress about the threat of drug counterfeiting
In testimony before the House Energy and Commerce Subcommittee on Health, a PhRMA executive argued that drug counterfeiting poses a threat to patient safety. Alan Goldhammer, PhRMA's deputy VP for scientific and regulatory affairs, urged passage of the Food & Drug Import Safety Act of 2007. The legislation is designed to strengthen FDA oversight for imports of food and drugs and would increase regulatory requirements for prescription drug repackagers, wholesalers, and distributors.
Click here to see more articles from Drug Topics Daily News.
